Associated Papers
Differences in intracellular localisation of ANKH mutants that relate to mechanisms of calcium pyrophosphate deposition disease and craniometaphyseal dysplasia.
Vijen S et al.
Scientific Reports, 2020
Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia.
Gruber BL et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, 2012
Novel ANKH mutation in a patient with sporadic craniometaphyseal dysplasia.
Zajac A et al.
American Journal of Medical Genetics. Part A, 2010
The CPPDD-associated ANKH M48T mutation interrupts the interaction of ANKH with the sodium/phosphate cotransporter PiT-1.
Wang J et al.
The Journal of Rheumatology, 2009
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear?
Reginato AM et al.
Current Opinion in Rheumatology, 2007
The new bone biology: pathologic, molecular, and clinical correlates.
Cohen MM
American Journal of Medical Genetics. Part A, 2006
P5L mutation in Ank results in an increase in extracellular inorganic pyrophosphate during proliferation and nonmineralizing hypertrophy in stably transduced ATDC5 cells.
Zaka R et al.
Arthritis Research & Therapy, 2006
Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease.
Williams CJ et al.
Arthritis and Rheumatism, 2003
Familial calcium pyrophosphate dihydrate deposition disease and the ANKH gene.
Williams CJ
Current Opinion in Rheumatology, 2003
Select a paper to view details